EGFR exon 19 deletion & L858R
Exon 19 deletion and L858R are the two common EGFR mutations, together ~85% of EGFR-mutant lung cancer, and both respond to EGFR pills.
Exon 19 deletions (~45%) respond somewhat better than L858R (~40%) to osimertinib; both are covered by first-line osimertinib, amivantamab-lazertinib, and osimertinib-chemotherapy. Uncommon mutations (G719X, L861Q, S768I) respond to afatinib; exon 20 insertions need amivantamab or sunvozertinib.
Pages like this
not linked directly; found by shared links- PersonDae Ho Lee
Shares Lazertinib, Amivantamab, Osimertinib, EGFR.
- PairingAmivantamab + lazertinib (first-line EGFR NSCLC)
Shares Lazertinib, Amivantamab, Osimertinib, EGFR.
- InstitutionGuangdong Provincial People's Hospital
Shares Gefitinib, Erlotinib, Osimertinib, EGFR.
- TermEGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)
Shares Gefitinib, Erlotinib, Osimertinib, EGFR.
- TermEGFR exon 20 insertion
Shares Amivantamab, Receptor tyrosine kinase activation, EGFR, Non-small-cell lung cancer.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Amivantamab, Osimertinib, EGFR, Non-small-cell lung cancer.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- TermMET amplification (bypass resistance)
Shares Amivantamab, Receptor tyrosine kinase activation, EGFR, Non-small-cell lung cancer.